OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain

Phase 3positiveUrcosimodPositive

AI Analysis

Summary

OKYO Pharma received positive feedback from an FDA Type D meeting regarding urcosimod and is advancing the drug into a global Phase 3 pivotal trial for neuropathic corneal pain.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Positive feedback from FDA Type D meeting; advancement to global Phase 3 pivotal trial

Importance:7/10

Sentiment:

0.80

FDA MeetingPhase 3OphthalmologyClinical Development

Related Companies

$OKYO

Read the original article

Published by yahoo_finance on July 8, 2026 11:00 AM

Read Original